BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016; 22(32): 7252-7263 [PMID: 27621572 DOI: 10.3748/wjg.v22.i32.7252]
URL: https://www.wjgnet.com/1948-5182/full/v22/i32/7252.htm
Number Citing Articles
1
Wenjie Zheng, Min Yao, Qi Qian, Wenli Sai, Liwei Qiu, Junling Yang, Wei Wu, Zhizhen Dong, Dengfu Yao. Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular targetOncotarget 2017; 8(32): 52321 doi: 10.18632/oncotarget.13674
2
Astrid Ruiz-Margáin, Berenice M Román-Calleja, Paulina Moreno-Guillén, José A González-Regueiro, Deyanira Kúsulas-Delint, Alejandro Campos-Murguía, Nayelli C Flores-García, Ricardo Ulises Macías-Rodríguez. Nutritional therapy for hepatocellular carcinomaWorld Journal of Gastrointestinal Oncology 2021; 13(10): 1440-1452 doi: 10.4251/wjgo.v13.i10.1440
3
Shunsuke Doi, Satoshi Yasuda, Yasuko Matsuo, Takeshi Sakata, Satoshi Nishiwada, Minako Nagai, Kota Nakamura, Taichi Terai, Yuichiro Kohara, Masayuki Sho. Clinical impact of sarcopenia in early-stage intrahepatic recurrent hepatocellular carcinoma: an association with impaired host immunityLangenbeck's Archives of Surgery 2023; 408(1) doi: 10.1007/s00423-023-03170-2
4
Hui Peng, Yingfei Wang, Weibo Luo. Multifaceted role of branched-chain amino acid metabolism in cancerOncogene 2020; 39(44): 6747 doi: 10.1038/s41388-020-01480-z
5
Wan-Shui Yang, Xu-Fen Zeng, Zhi-Ning Liu, Qi-Hong Zhao, Yu-Ting Tan, Jing Gao, Hong-Lan Li, Yong-Bing Xiang. Diet and liver cancer risk: a narrative review of epidemiological evidenceBritish Journal of Nutrition 2020; 124(3): 330 doi: 10.1017/S0007114520001208
6
Joshua P. Gray, Natalia Suhali-Amacher, Sidhartha D. Ray. A Worldwide Yearly Survey of New Data in Adverse Drug ReactionsSide Effects of Drugs Annual 2017; 39: 197 doi: 10.1016/bs.seda.2017.07.001
7
Yu-Lun Tsai, Pei-Chieh Yu, Hsin-Hua Nien, Tzu-Pin Lu. Time variation of high-risk groups for liver function deteriorations within fluctuating long-term liver function after hepatic radiotherapy in patients with hepatocellular carcinomaEuropean Journal of Medical Research 2024; 29(1) doi: 10.1186/s40001-024-01692-z
8
Jeong Won Lee, Sang Hyun Hwang, Hyun Jeong Kim, Dongwoo Kim, Arthur Cho, Mijin Yun. Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resectionEuropean Journal of Nuclear Medicine and Molecular Imaging 2017; 44(12): 1984 doi: 10.1007/s00259-017-3764-7
9
Cory Szybala, Mollie Parker Szybala, Peter B. Bongiorno. Textbook of Natural Medicine2020; : 1358 doi: 10.1016/B978-0-323-43044-9.00176-X
10
Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Reo Kawano, Takuro Hisanaga, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular CarcinomaLiver Cancer 2018; 7(4): 359 doi: 10.1159/000487858
11
Denise Bellotti, Maurizio Remelli. Deferoxamine B: A Natural, Excellent and Versatile Metal ChelatorMolecules 2021; 26(11): 3255 doi: 10.3390/molecules26113255
12
Mohammed Yusuf Ansari, Alhusain Abdalla, Mohammed Yaqoob Ansari, Mohammed Ishaq Ansari, Byanne Malluhi, Snigdha Mohanty, Subhashree Mishra, Sudhansu Sekhar Singh, Julien Abinahed, Abdulla Al-Ansari, Shidin Balakrishnan, Sarada Prasad Dakua. Practical utility of liver segmentation methods in clinical surgeries and interventionsBMC Medical Imaging 2022; 22(1) doi: 10.1186/s12880-022-00825-2
13
Issei Saeki, Takahiro Yamasaki, Yurika Yamauchi, Taro Takami, Tomokazu Kawaoka, Shinsuke Uchikawa, Akira Hiramatsu, Hiroshi Aikata, Reo Kawano, Kazufumi Kobayashi, Takayuki Kondo, Sadahisa Ogasawara, Tetsuhiro Chiba, Kazuaki Chayama, Naoya Kato, Isao Sakaida. Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular CarcinomaCancers 2021; 13(9): 2247 doi: 10.3390/cancers13092247